Replies to post #37888 on Biotech Values

[go seek]

Good to see a initiation positive from Susquehanna Finiancial.

My hope is several good news items are reported before year end... the drivers... pls add as you wish
1. no significant interaction between NM283 and Ribivarin in vivo
2. revelation of "creative" ideas on reduction of GI effect with higher doses on NM283 in treatment refractory
3. announcement on HIV choice to move forward
4. more positiive initiations and upgrades...
5. more approvals on Sebivo in rest of world.
6. strong launch of the NVS / IDIX HBV product
7. good news on possible HBV complement drug
8. positive PR from NVS on IDIX pipeline

the next quarter should bring a lot of news on the IDIX front

Cheers